You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
華領醫藥(02552.HK)急彈16% 獲瑞銀重申「買入」評級
阿思達克 11-15 11:09

獲瑞銀重申「買入」華領醫藥(02552.HK)扭轉連日尋底弱勢,股價急彈16%報4.77元,成交130萬股。

瑞銀指,華領日前公布旗下糖尿病治療的Dorzagliatin單藥療法III期臨床研究(HMM0301)24周研究結果數據表現不俗,但股價卻應聲下跌,相信是由於流動性不足導致投資者離場。該行指,華領未來12個月將出現不少股價催化劑,包括市場非常關注明年次季公布的HMM0301 52周結果、首季公布HMM0302 24周結果、Dorzagliatin或於明年底遞交上市申請,以及公司未來或與國際藥企達成潛在合作,維持華領「買入」評級,以反映公司手持1.8億美元現金流,估值約6億美元屬吸引,但目標價下調9.7%至12.1元,以反映考慮到產品商業化時間表延至明年底,預期Dorzagliatin要到2021年才可銷售。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account